Protein misfolding and aggregation is observed in many amyloidogenic diseases affecting
either the central nervous system or a variety of peripheral tissues. Structural and dynamic …

Self-assembled peptide and protein amyloid nanostructures have traditionally been
considered only as pathological aggregates implicated in human neurodegenerative …

Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi®) and
aducanumab (Aduhelm®)—have been approved in the USA for the treatment of Alzheimer's …

Preventing aggregation of amyloid beta (Aβ) peptides is a promising strategy for the
treatment of Alzheimer's disease (AD), and gold nanoparticles have previously been …

Self-assembled peptide nanostructures have been increasingly exploited as functional
materials for applications in biomedicine and energy. The emergent properties of these …

Optimized theranostic strategies for Alzheimer's disease (AD) remain almost absent from
bench to clinic. Current probes and drugs attempting to prevent β‐amyloid (Aβ) fibrosis …

Alzheimer's disease (AD) challenges our society with an annual estimated cost of $1.08
trillion in the United States alone by 2050. 1 AD is a progressive irreversible neurological …

Alzheimer's Disease (AD) is a neurodegenerative disorder related with the increase of age
and it is the main cause of dementia in the world. AD affects cognitive functions, such as …

Most common neurodegenerative diseases feature deposition of protein amyloids and
degeneration of brain networks. Amyloids are ordered protein assemblies that can act as …

Amyloidogenesis has been implicated in a broad spectrum of diseases in which amyloid
protein is invariably misfolded and deposited in cells and organs. Alzheimer's disease is one …